BioMarin resubmits marketing authorisation application to European Medicines Agency for valoctocogene roxaparvovec to treat severe haemophilia A

BioMarin

28 June 2021 - Valoctocogene roxaparvovec MAA granted request for accelerated assessment.

BioMarin Pharmaceutical announced today that the company resubmitted a marketing authorisation application to the EMA for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe haemophilia A.

Read BioMarin press release  

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Europe , Dossier , Gene therapy